Cookies on the JDRF website

Our website uses cookies to make your experience as great as possible. By continuing to use the website, we will assume that you agree to the use of cookies on the website. However, if you would like to change your cookie settings, please visit the website of The Information Commissioner's Office to find out how to control or delete cookies on your browser.

All news

Find out the latest news about JDRF's research and fundraising events.

Displaying partnerships


Coming to a TV near you - JDRF on the podium

JDRF was at Oulton Park race track in Cheshire on 8 June to officially launch a brand new partnership with Formula Ford.

Formula Ford in Britain is a major championship for young drivers, and has launched the careers of Formula One legend Ayrton Senna and 2009 Formula One World Champion Jenson Button. In support of our partnership, all Formula Ford drivers and teams have generously donated advertising space on their cars to JDRF – with our logo proudly displayed on the nose.

Ford Motor Company has supported JDRF for over 30 years, but this is our first venture into racing and we couldn’t be more excited. What makes this partnership even more special is that JDRF supporter Andy Richardson is racing with Formula Ford this season.  Andy has type 1 diabetes, but he doesn’t let that stop him fighting for a podium finish.

Andy said: ‘Living with type 1 diabetes hasn’t prevented me from pursuing my racing career, but it has thrown up extra challenges that I have worked to overcome. When I was diagnosed, I was old enough to be able to understand and deal with those challenges, but that isn’t the case for a lot of younger people who suffer difficulties in their lives because of type 1.’

He added: ‘The work that JDRF carries out to try to find the cure for type 1 is fantastic, and I’m pleased that both myself and my rivals on track will be promoting that work throughout the year.’

Formula Ford is helping JDRF raise awareness and vital funds for type 1 diabetes research throughout the rest of this season, so watch out for JDRF when races are screened on ITV4.

You can read the full story on the British Formula Ford website.


New vision for type 1 diabetes

JDRF has joined forces with UK biotech company KalVista to bring hope to type 1 diabetes patients at risk of vision complications.

This new research collaboration will help KalVista begin first in human trials with a new drug they have developed to treat diabetic retinopathy.

KalVista are working on a therapy that may improve or delay the symptoms of diabetic eye disease. The drug may help to protect the blood vessels in the eye that are often damaged in diabetic eye disease and can lead to vision loss. They hope that protecting these blood vessels may prevent or slow down vision problems. The new drug can be delivered straight to the eye and this study aims to tests its safety in humans.

Diabetic eye disease or diabetic retinopathy is the most common and most serious eye related complication in patients with type 1 diabetes. It causes swelling of part of the eye and destroys small blood vessels leading to loss of vision. A treatment to prevent or slow its progression would be a major benefit to patients.

The partnership with KalVista is particularly important as it allows this novel therapy, move from basic research – which was also supported by JDRF – towards clinical testing.

Head of research communication at JDRF Rachel Connor said ‘we are very excited about this partnership with KalVista and believe that this approach could make a difference to thousands of people affected by type 1 diabetes at risk of diabetic retinopathy’.


JDRF partners with Selecta Biosciences to develop possible vaccine for type 1 diabetes

JDRF has announced a new research collaboration to support the development of a vaccine which may help better treat and potentially prevent type 1 diabetes.

The partnership with Selecta Biosciences will see JDRF provide expertise and financial support, with the goal of applying Selecta’s vaccine technology toward the development of vaccines for type 1 diabetes.

Selecta is working on a type of therapy called an ‘antigen-specific tolerogenic vaccine’. This is designed to specifically target the parts of the immune system that cause type 1 diabetes, without damaging the rest of the immune system. In addition to its potential in preventing type 1 diabetes, this type of diabetes vaccine could have other benefits. For example, they could be used in conjunction with other therapies to preserve remaining beta cell function in individuals recently diagnosed with type 1 diabetes. It may also help with regeneration and replacement therapies, and be used to protect newly regenerated or transplanted insulin-producing beta cells in established type 1 diabetes

JDRFI Chief Scientific Officer said: “We believe vaccine research is one of the most promising approaches to prevent or halt the beta cell-specific autoimmunity in type 1 diabetes. And we are excited to be teaming up with Selecta to support the development of this next-generation of vaccine technology.”

The research collaboration agreement between JDRF and Selecta is part of JDRF's Industry Discovery and Development Partnership (IDDP) program. Through this, JDRF partners with pharmaceutical, biotechnology, and medical device companies to prioritise and speed the discovery, development, and delivery of therapies and devices for type 1 diabetes.


JDRF and Amylin partner to explore if mixing human hormone with insulin could better treat type 1

Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals have today announced that they will be working together to fund a series of clinical studies testing the use of amylin in type 1 diabetes treatment. The research will establish whether mixing the drug pramlintide, a man-made version of the human hormone amylin, with insulin could improve blood glucose control in people with type 1 diabetes, compared to the use of insulin alone.

In a healthy pancreas, both insulin and amylin are produced and released by the same cells. The two hormones work together to help stabilise blood glucose levels. Insulin helps the body regulate production and storage of glucose, while amylin helps control the rate at which glucose enters the blood after meals.

Currently, patients who use pramlintide must separately administer their daily insulin therapy, either through injections or an insulin pump. Creating a mixture of the two drugs that still offers the benefits of both hormones, might better mimic the way a healthy pancreas works.

This is the second research partnership between JDRF and Amylin working to improve treatments for people with type 1 diabetes. The project is part of JDRF’s Industry Discovery and Development Partnership (IDDP) program aiming to accelerate research that will lead to better treatments and a cure for type 1 diabetes.

Eleanor Kennedy, Head of Research Communication at JDRF said, ‘ It will be interesting to see whether mixing pramlintide with insulin has the potential to help people with type 1 diabetes tighten their glucose control. We look forward to seeing the outcomes of the research resulting from this partnership.”